JP2000502570A - Ｆｈｉｔタンパク質および核酸ならびにそれに基づく方法 - Google Patents

Ｆｈｉｔタンパク質および核酸ならびにそれに基づく方法

Info

Publication number
JP2000502570A
JP2000502570A JP9528665A JP52866597A JP2000502570A JP 2000502570 A JP2000502570 A JP 2000502570A JP 9528665 A JP9528665 A JP 9528665A JP 52866597 A JP52866597 A JP 52866597A JP 2000502570 A JP2000502570 A JP 2000502570A
Authority
JP
Japan
Prior art keywords
fhit
protein
sequence
nucleic acid
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9528665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000502570A5 (enExample
Inventor
クロース，カルロ，エム．
ヒューブナー，フランシス，ケイ．
Original Assignee
トーマス ジェファーソン ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/598,873 external-priority patent/US5928884A/en
Application filed by トーマス ジェファーソン ユニバーシティー filed Critical トーマス ジェファーソン ユニバーシティー
Publication of JP2000502570A publication Critical patent/JP2000502570A/ja
Publication of JP2000502570A5 publication Critical patent/JP2000502570A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP9528665A 1996-02-09 1997-02-07 Ｆｈｉｔタンパク質および核酸ならびにそれに基づく方法 Ceased JP2000502570A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/598,873 1996-02-09
US08/598,873 US5928884A (en) 1996-02-09 1996-02-09 FHIT proteins and nucleic acids and methods based thereon
US08/605,430 1996-02-22
US08/605,430 US6242212B1 (en) 1996-02-09 1996-02-22 Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
PCT/US1997/001937 WO1997029119A1 (en) 1996-02-09 1997-02-07 Fhit proteins and nucleic acids and methods based thereon

Publications (2)

Publication Number Publication Date
JP2000502570A true JP2000502570A (ja) 2000-03-07
JP2000502570A5 JP2000502570A5 (enExample) 2004-11-18

Family

ID=27083164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9528665A Ceased JP2000502570A (ja) 1996-02-09 1997-02-07 Ｆｈｉｔタンパク質および核酸ならびにそれに基づく方法

Country Status (7)

Country Link
US (5) US6242212B1 (enExample)
EP (2) EP0892809B1 (enExample)
JP (1) JP2000502570A (enExample)
AT (1) ATE327326T1 (enExample)
AU (1) AU2262197A (enExample)
DE (1) DE69735939T2 (enExample)
WO (1) WO1997029119A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276879A4 (en) * 2000-04-11 2004-12-22 Univ Jefferson MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE
WO2002064171A1 (en) * 2001-02-12 2002-08-22 Thomas Jefferson University Adenoviral transduction of fragile histidine triad (fhit) into cancer cells
WO2002064172A2 (en) * 2001-02-12 2002-08-22 Thomas Jefferson University Fhit gene therapy prevents tumor development in fhit-deficient mice
WO2004082458A2 (en) 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
CN1822853A (zh) * 2003-07-15 2006-08-23 加拿大国家研究委员会 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物
US7433520B1 (en) * 2004-12-01 2008-10-07 Kilimanjaro Partnership Nosologic system of diagnosis
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CA2621441C (en) * 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007098954A1 (en) * 2006-03-03 2007-09-07 Ciemat A mouse model comprising an engrafted human skin having hypersensitivity to uv-light
EP2369013A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
US20100021895A1 (en) * 2006-07-12 2010-01-28 Ruley H Earl Vectors for Inducing Homozygous Mutations and Methods of Using Same
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
CA2663027A1 (en) * 2006-09-19 2008-08-14 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
CN103555825B (zh) * 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
WO2008136971A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
CN101711287B (zh) * 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
AU2008266014B2 (en) * 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
US20090023138A1 (en) * 2007-07-17 2009-01-22 Zila Biotechnology, Inc. Oral cancer markers and their detection
CN101809169B (zh) * 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2173908B1 (en) * 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultraconserved regions encoding ncrnas
CA2926831A1 (en) * 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CA2698771A1 (en) * 2007-09-06 2009-03-12 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
CN103937876B (zh) * 2007-10-11 2016-08-17 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
US20110054009A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
CA2727633A1 (en) 2008-06-11 2009-12-17 Xin W. Wang Use of mir-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
CN103648505B (zh) 2010-11-12 2016-09-28 俄亥俄州立大学研究基金会 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US5352775A (en) * 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
CA2060267A1 (en) * 1991-02-22 1992-08-23 Joe W. Gray Chromosome specific staining to detect genetic rearrangements
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
DE69735939D1 (de) 2006-06-29
EP0892809A4 (en) 2002-10-09
EP0892809B1 (en) 2006-05-24
US20050074797A1 (en) 2005-04-07
DE69735939T2 (de) 2007-01-25
US20070178105A1 (en) 2007-08-02
ATE327326T1 (de) 2006-06-15
WO1997029119A1 (en) 1997-08-14
EP1795203A2 (en) 2007-06-13
US20040265316A1 (en) 2004-12-30
US6242212B1 (en) 2001-06-05
US7220834B2 (en) 2007-05-22
EP1795203A3 (en) 2007-07-04
AU2262197A (en) 1997-08-28
US6774217B1 (en) 2004-08-10
EP0892809A1 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
US6242212B1 (en) Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US5928884A (en) FHIT proteins and nucleic acids and methods based thereon
AU766675B2 (en) Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
US7749715B2 (en) TCL-1 gene and protein and related methods and compositions
US7175995B1 (en) TCL-1 protein and related methods
JP2001504333A (ja) 前立腺特異カリクレイン
JP2000515734A (ja) ヒトｃＡＭＰ依存性プロテインキナーゼインヒビターホモログ
EP0817798A1 (en) Nucleotide and protein sequences of lats genes and methods based thereon
JP2001523096A (ja) 乳癌の診断および治療のための方法ならびに組成物
JP2002506875A (ja) 第１８ｐ染色体関連障害の診断及び治療のための方法及び組成物
US5874290A (en) Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon
JP2004525628A (ja) 新規な天然の抗菌性ペプチド、該ペプチドをコードするヌクレオチド配列及びそれらの使用
US20040047845A1 (en) Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
US5990294A (en) Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof
CA2245783A1 (en) Fhit proteins and nucleic acids and methods based thereon
CN100425695C (zh) 新型人Rab GTP酶，其编码序列及用途
CN1919868B (zh) 慢性神经痛相关蛋白及其基因
JP2001517944A (ja) 新規なヒトサイトカイン／ステロイド受容体タンパク質
WO2009030088A1 (fr) Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline
JP2001514507A (ja) 癌の診断と治療のための方法および組成物
AU3291799A (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106